arrow
H

Hong, David S.

university of texas system
H指数:0
被引数:18

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Clinical and Genomic Landscape of RAS Mutations in Gynecologic Cancers
2024-04-303
PRE
Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101)

生物标志物匹配疗法对参加早期临床试验的肉瘤患者结局的影响 (SAMBA 101)

2023-04-148
OAAI
Eganelisib, a First-in-Class PI3Kg Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial

Eganelisib,一类PI3Kg抑制剂,用于晚期实体瘤患者: 1/1b期MARIO-1试验的结果

2023-03-3126
OA
Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102)

检查斑马群的条纹: 在1期临床试验中基因组匹配对超级肉瘤的影响 (SAMBA 102)

2022-10-264
OAAI
Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma
2022-06-0191
OAAI
A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies
2021-03-2636
OA
Phase I Study of Everolimus, Letrozole, and Trastuzumab in Patients with Hormone Receptor-positive Metastatic Breast Cancer or Other Solid Tumors
2021-03-018
OAAI
Intratumoral Injection of Clostridium novyi-NT Spores in Patients with Treatment-refractory Advanced Solid Tumors
2021-01-0485
OAAI
Phase I Study of P-cadherin-targeted Radioimmunotherapy with 90Y-FF-21101 Monoclonal Antibody in Solid Tumors
2020-11-1322
OAAI
Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma
2020-11-0223
OAAI
Evaluating the psychometric properties of the Immunotherapy module of the MD Anderson Symptom Inventory

评估MD安德森症状量表的免疫治疗模块的心理计量学特性

2020-10-2312
OAAI
First-in-human phase I study of immunomodulatory E7046, an antagonist of PGE 2-receptor E-type 4 (EP4), in patients with advanced cancers
2020-06-1752
OAAI
Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer

无细胞循环肿瘤DNA变异等位基因频率与转移性癌症的生存相关

2020-04-1548
OAAI
Phase 2 study of pembrolizumab in patients with advanced rare cancers
2020-03-1774
OAAI
Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer
2020-03-1390
OAAI